Strategies for designing and optimizing new generation vaccines

Nature Reviews Immunology

Volumn 1, Issue 3, 2001, Pages 209-219

  Berzofsky, Jay A ^a   Ahlers, Jeffrey D ^a   Belyakov, Igor M ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; DNA VACCINE; EPITOPE; IMMUNOLOGICAL ADJUVANT; VACCINE;

ANIMAL; BIOLOGICAL MODEL; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DRUG DESIGN; HUMAN; IMMUNOLOGY; ISOLATION AND PURIFICATION; MUCOSAL IMMUNITY; REVIEW;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; CYTOKINES; DENDRITIC CELLS; DRUG DESIGN; EPITOPES; HUMANS; IMMUNITY, MUCOSAL; MODELS, IMMUNOLOGICAL; T-LYMPHOCYTES, CYTOTOXIC; VACCINES; VACCINES, DNA;

EID: 0035751961     PISSN: 14741733     EISSN: None     Source Type: Journal    
DOI: 10.1038/35105075     Document Type: Review

References (178)

1. Berzofsky, J. A. et al. Approaches to improve engineered vaccines for human immunodeficiency virus (HIV) and other viruses that cause chronic infections. Immunol. Rev. 170, 151-172 (1999).
2. Berzofsky, J. A. Epitope selection and design of synthetic vaccines: molecular approaches to enhancing immunogenicity and crossreactivity of engineered vaccines. Ann. NY Acad. Sci. 690, 256-264 (1993).
3. + T cell tolerance to peripherally expressed antigens. J. Immunol. 163, 723-727 (1999).
4. Sandberg, J. K. et al. T cell tolerance based on avidity thresholds rather than complete deletion allows maintenance of maximal repertoire diversity. J. Immunol. 165, 25-33 (2000).
5. +0201-restricted human immunodeficiency virus pol peptide increases complex stability and in vitro immunogenicity. Proc. Natl Acad. Sci. USA 92, 8166-8170 (1995).
6. Sarobe, P. et al. Enhanced in vitro potency and in vivo immunogenicity of a CTL epitope from hepatitis C virus core protein following amino acid replacement at secondary HLA-A2.1 binding positions. J. Clin. Invest. 102, 1239-1248 (1998).
7. +0201 -binding residues. J. Immunol. 157, 2539-2548 (1996).
8. Rosenberg, S. A. et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nature Med. 4, 321-327 (1998).
9. Irvine, K. R. et al. Recombinant virus vaccination against 'self' antigens using anchor-fixed immunogens. Cancer Res. 59, 2536-2540 (1999).
10. Ahlers, J. D., Takeshita, T., Pendleton, C. D. & Berzofsky, J. A. Enhanced immunogenicity of HIV-1 vaccine construct by modification of the native peptide sequence. Proc. Natl Acad. Sci. USA 94, 10856-10861 (1997).
11. Ahlers, J. D., Belyakov, I. M., Thomas, E. K. & Berzofsky, J. A. High affinity T-helper epitope induces complementary helper and APC polarization, increased CTL and protection against viral infection. J. Clin. Invest. 108, 1677-1685 (2001).
12. Rammensee, H.-G., Friede, T. & Stevanovic, S. MHC ligands and peptide motifs: first listing. Immunogenetics 41, 178-228 (1995).
13. Ruppert, J. et al. Prominent role of secondary anchor residues in peptide binding to HLA-A2.1 molecules. Cell 74, 929-937 (1993).
14. Alexander, J. et al. Development of high potency universal DR-restricted helper epitopes by modification of high affinity DR-blocking peptides. Immunity 1, 751-761 (1994).
15. La Rosa, C. et al. Enhanced immune activity of cytotoxic T-lymphocyte epitope analogs derived from positional scanning synthetic combinatorial libraries. Blood 97, 1776-1786 (2001).
16. Slansky, J. E. et al. Enhanced antigen-specific antitumor immunity with altered peptide ligands that stabilize the MHC-peptide-TCR complex. Immunity 13, 529-538 (2000).
17. Zaremba, S. et al. Identification of an enhancer agonist cytotoxic T lymphocyte peptide from human carcinoembryonic antigen. Cancer Res. 57, 4570-4577 (1997).
18. Fong, L. et al. Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy. Proc. Natl Acad. Sci. USA 98, 8809-8814 (2001).
19. Tangri, S. et al. Structural features of peptide analogs of human histocompatibility leukocyte antigen class I epitopes that are more potent and immunogenic than wild-type peptide. J. Exp. Med. 194, 833-846 (2001).
20. Takahashi, H. et al. Induction of broadly cross-reactive cytotoxic T cells recognizing an HIV-1 envelope determinant. Science 255, 333-336 (1992).
21. Alexander-Miller, M. A., Leggatt, G. R. & Berzofsky, J. A. Selective expansion of high or low avidity cytotoxic T lymphocytes and efficacy for adoptive immunotherapy. Proc. Natl Acad. Sci. USA 93, 4102-4107 (1996).
22. Gallimore, A., Dumrese, T., Hengartner, H., Zinkernagel, R. M. & Rammensee, H. G. Protective immunity does not correlate with the hierarchy of virus-specific cytotoxic T cell responses to naturally processed peptides. J. Exp. Med. 187, 1647-1657 (1998).
23. Zeh, H. J. III, Perry-Lalley, D., Dudley, M. E., Rosenberg, S. A. & Yang, J. C. High avidity CTLs for two self-antigens demonstrate superior in vitro and in vivo antitumor efficacy. J. Immunol. 162, 989-994 (1999).
24. Yee, C., Savage, P. A., Lee, P. P., Davis, M. M. & Greenberg, P. D. Isolation of high avidity melanoma-reactive CTL from heterogeneous populations using peptide-MHC tetramers. J. Immunol. 162, 2227-2234 (1999).
25. Derby, M. A., Wang, J., Margulies, D. H. & Berzofsky, J. A. Two intermediate avidity CTL clones with a disparity between functional avidity and MHC tetramer staining. Int. Immunol. 13, 817-824 (2001).
26. + T cells without selection of higher affinity TCR. Nature Immunol. 2, 711-717 (2001).
27. Margulies, D. H. TCR avidity: it's not how strong you make it, it's how you make it strong. Nature Immunol. 2, 669-670 (2001).
28. Cawthon, A. G., Lu, H. & Alexander-Miller, M. A. Peptide requirement for CTL activation reflects the sensitivity to CD3 engagement: correlation with CD8αβ versus CD8αα expression. J. Immunol. 167, 2577-2584 (2001).
29. Fahmy, T. M., Bieler, J. G., Edidin, M. & Schneck, J. P. Increased TCR avidity after T cell activation. A mechanism for sensing low-density antigen. Immunity 14, 135-143 (2001).
30. Alexander-Miller, M. A., Leggatt, G. R., Sarin, A. & Berzofsky, J. A. Role of antigen, CD8, and cytotoxic T lymphocyte avidity in high dose antigen induction of apoptosis of effector CTL. J. Exp. Med. 184, 485-492 (1996).
31. Alexander-Miller, M. A., Derby, M. A., Sarin, A., Henkart, P. A. & Berzofsky, J. A Supra-optimal peptide/MHC causes a decrease in Bcl-2 and allows TNF-α receptor II-mediated apoptosis of CTL. J. Exp. Med. 188, 1391-1399 (1998).
32. Zheng, L. et al. Induction of apoptosis in mature T cells by tumour necrosis factor. Nature 377, 348-351 (1995).
33. Derby, M. A., Alexander-Miller, M. A., Tse, R. & Berzofsky, J. A. High avidity CTL exploit two complementary mechanisms to provide better protection against viral infection than low avidity CTL J. Immunol. 166, 1690-1697 (2001).
34. Kawamura, H., Rosenberg, S. A. & Berzofsky, J. A. Immunization with antigen and interleukin-2 in vivo overcomes lr gene low responsiveness. J. Exp. Med. 162, 381-386 (1985).
35. Good, M. F. et al. Recombinant human interleukin-2 (IL-2) overcomes genetic nonresponsiveneas to malaria sporozoite peptides. Correlation of effect with biological activity of IL-2. J. Immunol. 141, 972-977 (1988).
36. Ahlers, J. D., Dunlop, N., Alling, D. W., Nara, P. L. & Berzofsky, J. A. Cytokine-in-adjuvant steering of the immune response phenotype to HIV-1 vaccine constructs: GM-CSF and TNFα synergize with IL-12 to enhance induction of CTL. J. Immunol. 158, 3947-3958 (1997).
37. Disis, M. L. et al. Granulocyte-macrophage colony-stimulating factor: an effective adjuvant for protein and peptide-based vaccines. Blood 88, 202-210 (1996).
38. Belyakov, I. M., Ahlers, J. D., Clements, J. D., Strober, W. & Berzofsky, J. A. Interplay of cytokines and adjuvants in the regulation of mucosal and systemic HIV-specific cytotoxic T lymphocytes. J. Immunol. 165, 6454-6462 (2000).
39. Xiang, Z. & Ertl, H. C. J. Manipulation of the immune response to a plasmid-encoded viral antigen by coinoculation with plasmids expressing cytokines. Immunity 2, 129-135 (1995).
40. Kim, J. J. et al. Modulation of amplitude and direction of in vivo immune responses by co-administration of cytokine gene expression cassettes with DNA immunogens. Eur. J. Immunol. 28, 1089-1103 (1998).
41. Iwasaki, A., Stiernholm, B. J. N., Chan, A. K., Berinstein, N. L. & Barber, B. H. Enhanced CTL responses mediated by plasmid DNA immunogens encoding costimulatory molecules and cytokines. J. Immunol. 158, 4591-4601 (1997).
42. Scheerlinck, J. Y. Genetic adjuvants for DNA vaccines. Vaccine 19, 2647-2656 (2001).
43. Dranoff, G. et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc. Natl Acad. Sci. USA 90, 3539-3543 (1993).
44. Flexner, C., Hügin, A. & Moss, B. Prevention of vaccinia virus infection in immunodeficient mice by vector-directed IL-2 expression. Nature 330, 259-262 (1987).
45. Ramshaw, I. A., Andrew, M. E., Phillips, S. M., Boyle, D. B. & Coupar, B. E. Recovery of immunodeficient mice from a vaccinia virus/IL-2 recombinant infection. Nature 329, 545-546 (1987).
46. Barouch, D. H. et al. Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination. Science 290, 486-492 (2000).
47. + T cells in vivo by IL-15. Immunity 8, 591-599 (1998).
48. + memory T cells by opposing cytokines. Science 288, 675-678 (2000).
49. Waldmann, T. A., Dubois, S. & Tagaya, Y. Contrasting roles of IL-2 and IL-15 in the life and death of lymphocytes: implications for immunotherapy. Immunity 14, 105-110 (2001).
50. Xin, K. Q. et al. IL-15 expression plasmid enhances cell-mediated immunity induced by an HIV-1 DNA vaccine. Vaccine 17, 858-856 (1999).
51. Ahlers, J. D., Belyakov, I. M., Matsui, S. & Berzofsky, J. A. Mechanisms of cytokine synergy essential for vaccine protection against viral challenge. Int. Immunol. 13, 897-908 (2001).
52. Ahlers, J. D., Belyakov, I. M., Matsui, S. & Berzofsky, J. A. Signals delivered through TCR instruct IL-12R expression: IL-12 and TNFα synergize for IL-12R expression at low antigen dose. Int. Immunol. 13, 1433-1442 (2001).
53. Chamberlain, R. S. et al. Costimulation enhances the active immunotherapy effect of recombinant anticancer vaccines. Cancer Res. 56, 2832-2836 (1996).
54. Freund, Y. R. et al. Vaccination with recombinant vaccinia vaccine containing the B7-1 co-stimulatory molecule causes no significant toxicity and enhances T cell-mediated cytotoxicity. Int. J. Cancer 85, 508-517 (2000).
55. Kim, J. J. et al. Development of a multicomponent candidate vaccine for HIV-1. Vaccine 15, 879-883 (1997).
56. Rao, J. B. et al. IL-12 is an effective adjuvant to recombinant vaccinia virus-based tumor vaccines: enhancement by simultaneous B7-1 expression. J. Immunol. 156, 3357-3365 (1996).
57. Gurunathan, S. et al. CD40 ligand/trimer DNA enhances both humoral and cellular immune responses and induces protective immunity to infectious and tumor challenge. J. Immunol. 161, 4563-4571 (1998).
58. + T cell-mediated protective immunity against herpes simplex virus type 2 in vivo. Hum. Gene Ther. 12, 1091-1102 (2001).
59. Hodge, J. W. et al. A triad of costimulatory molecules synergize to amplify T-cell activation. Cancer Res. 59, 5800-5807 (1999).
60. Zhu, M. et al. Enhanced activation of human T cells via avipox vector-mediated hyperexpression of a triad of costimulatory molecules in human dendritic cells. Cancer Res. 61, 3725-3734 (2001).
61. Veazey, R. S. & Lackner, A. A. The gastrointestinal tract and the pathogenesis of AIDS. AIDS 12, S35-S42 (1998).
62. Baba, T. W. et al. Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection. Nature Med. 6, 200-206 (2000).
63. Mascola, J. R. et al. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nature Med. 6, 207-210 (2000).
64. + lymphocytes. Science 283, 857-860 (1999).
65. + T cell depletion in simian immunodeficiency virus-infected macaques. J. Exp. Med. 189, 991-998 (1999).
66. + lymphocyte responses in the cervix of HIV-1 -resistant prostitutes in nairobi. J. Immunol. 164, 1602-1611 (2000).
67. Betyakov, I. M. et al. Mucosal immunization with HIV-1 peptide vaccine induces mucosal and systemic cytotoxic T lymphocytes and protective immunity in mice against intrarectal recombinant HIV-vaccinia challenge. Proc. Natl Acad. Sci. USA 95, 1709-1714 (1998).
68. Belyakov, I. M. et al. Induction of mucosal CTL response by intrarectal immunization with a replication-deficient recombinant vaccinia virus expressing HIV 89.6 envelope protein. J. Virol. 72, 8264-8272 (1998).
69. + cytotoxic T lymphocytes for resistance to mucosal-viral transmission in mice and enhancement of resistance by local administration of IL-12. J. Clin. Invest. 102, 2072-2081 (1998).
70. Murphey-Corb, M. et al. Selective induction of protective MHC class I restricted CTL in the intestinal lamina propria of rhesus monkeys by transient SIV infection of the colonic mucosa. J. Immunol. 162, 540-549 (1999).
71. Eo, S. K., Gierynska, M., Kamar, A. A. & Rouse, B. T. Prime-boost immunization with DNA vaccine: mucosal route of administration changes the rules. J. Immunol. 166, 5473-5479 (2001).
72. + T lymphocytes by attenuated simian immunodeficiency virus. J. Virol. 74, 8762-8766 (2000).
73. Belyakov, I. M., Moss, B., Strober, W. & Berzofsky, J. A. Mucosal vaccination overcomes the barrier to recombinant vaccinia immunization caused by preexisting poxvirus immunity. Proc. Natl Acad. Sci. USA 96, 4512-4517 (1999).
74. + T cell depletion and viral replication in SIV infection. Science 280, 427-431 (1998).
75. Belyakov, I. M. et al. Mucosal AIDS vaccine reduces disease and viral load in gut reservoir and blood after mucosal infection of macaques. Nature Med. 7, 1320-1326 (2001).
76. Lehner, T. et al. Protective mucosal immunity elicited by targeted iliac lymph node immunization with a subunit SIV envelope and core vaccine in macaques. Nature Med. 2, 767-775 (1996).
77. Lehner, T., Bergmeier, L., Wang, Y., Tao, L. & Mitchell, E. A rational basis for mucosal vaccination against HIV infection. Immunol. Rev. 170, 183-196 (1999).
78. Mestecky, J. & Fultz, P. N. Mucosal immune system of the human genital tract. J. Infect. Dis. 179 (Suppl. 3), S470-S474 (1999).
79. Kozlowski, P. A., Cu-Uvin, S., Neutra, M. R. & Flanigan, T. P. Comparison of the oral, rectal, and vaginal immunization routes for induction of antibodies in rectal and genital tract secretions of women. Infect. Immun. 65, 1387-1394 (1997).
80. Lehner, T. et al. The effect of route of immunization on mucosal immunity and protection. J. Infect Dis. 179 (Suppl. 3), S489-S492 (1999).
81. Scharton-Kersten, T. et al. Transcutaneous immunization with bacterial ADP-ribosylating exotoxins, subunits, and unrelated adjuvants. Infect. Immun. 68, 5306-5313 (2000).
82. Dickinson, B. L. & Clements, J. D. Dissociation of Escherichia coli heat-labile enterotoxin adjuvanticity from ADP-ribosyltransferase activity. Infect. Immun. 63, 1617-1623 (1995).
83. Oliver, A. R. & Elson, C. O. Role of mucosal adjuvants in mucosal immunization. Curr. Opin. Gastroenterol. 14, 438-487 (1998).
84. Pizza, M. et al. Mucosal vaccines: non toxic derivatives of LT and CT as mucosal adjuvants. Vaccine 19, 2534-2541 (2001).
85. Czerkinsky, C. et al. Mucosal immunity and tolerance: relevance to vaccine development. Immunol. Rev. 170, 197-222 (1999).
86. Cheng, E., Cardenas-Freytag, L. & Clements, J. D. The role of cAMP in mucosal adjuvanticity of Escherichia coli heat-labile enterotoxin (LT). Vaccine 18, 38-49 (1999).
87. Braun, M. C., He, J., Wu, C.-Y. & Kelsall, B. L. Cholera toxin suppresses interleukin (1L)-12 production and IL-12 receptor B1 and B2 chain expression. J. Exp. Med. 189, 541-552 (1999).
88. Lehner, T. et al. The role of γδ cells in generating antiviral factors and β-chemokines in protection against mucosal simian immunodeficiency virus infection. Eur. J. Immunol. 30, 2245-2256 (2000).
89. Gallichan, W. S. et al. Intranasal immunization with CpG oligodeoxynucleotides an as adjuvant dramatically increases IgA and protection against herpes simplex virus-2 in the genital tract. J. Immunol. 166, 3451-3457 (2001).
90. Horner, A. A. et al. Immunostimulatory DNA-based vaccines elicit multifaceted immune responses against HIV at systemic and mucosal sites. J. Immunol. 167, 1584-1591 (2001).
91. H2)-type responses to an oral vaccine without altering mucosal IgA responses. J. Exp. Med. 185, 415-427 (1997).
92. + immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. J. Exp. Med. 188, 287-296 (1998).
93. + T cells: a common basis between tumor immunity and autoimmunity. J. Immunol. 163, 5211-5218 (1999).
94. + immunoregulatory T cells that control autoimmune diabetes. Immunity 12, 431-440 (2000).
95. + regulatory cells? Immunity 14, 399-406 (2001).
96. + immunoregulatory T cells is antigen nonspecific. J. Immunol. 164, 183-190 (2000).
97. Terabe, M. et al. Negative regulation of CTL-mediated tumour immunosurveillance through NKT cell induced IL-13 production and the IL-4R-STAT6 signal pathway. Nature Immunol. 1, 515-520 (2000).
98. Ostrand-Rosenberg, S., Grusby, M. J. & Clements, V. K. STAT6-deficient mice have enhanced tumor immunity to primary and metastatic mammary carcinoma. J. Immunol. 165, 6015-6019 (2000).
99. Kacha, A. K., Fallarino, F., Markiewicz, M. A. & Gajewski, T. F. Spontaneous rejection of poorly immunogenic P1.HTR tumors by Stat6-deficient mice. J. Immunol. 165, 6024-6028 (2000).
100. Krummel, M. F. & Allison, J. P. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J. Exp. Med. 182, 459-465 (1995).
101. Lee, K. M. et al. Molecular basis of T cell inactivation by CTLA-4. Science 282, 2263-2266 (1998).
102. Greenwald, R. J., Boussiotis, V. A., Lorsbach, R. B., Abbas, A. K. & Sharpe, A. H. CTLA-4 regulates induction of anergy in vivo. Immunity 14, 145-155 (2001).
103. + T cell-and IL-2-dependent mechanism. Immunity 11, 483-493 (1999).
104. Leach, D. R., Krummel, M. F. & Allison, J. P. Enhancement of anitumor immunity by CTLA-4 blockade. Science 271, 1734-1736 (1996).
105. + regulatory T cells in antitumor therapy reveals alternative cytotoxic T lymphocyte responses. J. Exp. Med. 194, 823-832 (2001).
106. Liu, M. A. & Ulmer, J. B. Gene-based vaccines. Mol. Ther. 1, 497-500 (2000).
107. Gurunathan, S., Klinman, D. M. & Seder, R. A. DNA vaccines: immunology, application, and optimization. Annu. Rev. Immunol. 18, 927-974 (2000).
108. Caley, I. J. et al. Venezuelan equine encephalitis virus vectors expressing HIV-1 proteins: vector design strategies for improved vaccine efficacy. Vaccine 17, 3124-3135 (1999).
109. Dubensky, T. W. Jr, Liu, M. A. & Ulmer, J. B. Delivery systems for gene-based vaccines. Mol. Med. 6, 723-732 (2000).
110. Leitner, W. W., Ying, H., Driver, D. A., Dubensky, T. W. & Restifo, N. P. Enhancement of tumor-specific immune response with plasmid DNA replicon vectors. Cancer Res. 60, 51-55 (2000).
111. Huang, Y., Kong, W. P. & Nabel, G. J. Human immunodeficiency virus type 1-specific immunity after genetic immunization is enhanced by modification of Gag and Pol expression. J. Virol. 75, 4947-4951 (2001).
112. Widera, G. et al. Increased DNA vaccine delivery and immunogenicity by electroporation in vivo. J. Immunol. 164, 4635-4640 (2000).
113. Iwasaki, A., Torres, C. A. T., Ohashi, P. S., Robinson, H. L. & Barber, B. H. The dominant role of bone marrow-derived cells in CTL induction following plasmid DNA immunization at different sites. J. Immunol. 159, 11-14 (1997).
114. + T cells after gene gun immunization. J. Exp. Med. 188, 1075-1082 (1998).
115. Fu, T. M. et al. Priming of cytotoxic T lymphocytes by DNA vaccines: requirement for professional antigen presenting cells and evidence for antigen transfer from myocytes. Mol. Med. 3, 362-371 (1997).
116. Tang, D., DeVit, M. & Johnston, S. A. Genetic immunization is a simple method for eliciting an immune response. Nature 356, 152-154 (1992).
117. Darji, A. et al. Oral somatic transgene vaccination using attenuated S. typhimurium. Cell 91, 765-775 (1997).
118. Woo, P. C., Wong, L. P., Zheng, B. J. & Yuen, K. Y. Unique immunogenicity of hepatitis B virus DNA vaccine presented by live-attenuated Salmonella typhimurium. Vaccine 19, 2945-2954 (2001).
119. Torres, C. A. T., Iwasaki, A., Barber, B. H. & Robinson, H. L. Differential dependence on target site tissue for gene gun and intramuscular DNA immunizations. J. Immunol. 158, 4529-4532 (1997).
120. Biragyn, A., Tani, K., Grimm, M. C., Weeks, S. & Kwak, L. W. Genetic fusion of chemokines to a self tumor antigen induces protective, T-cell dependent antitumor immunity. Nature Biotechnol. 17, 253-258 (1999).
121. Klinman, D. M., Yi, A. K., Beaucage, S. L., Conover, J. & Krieg, A. M. CpG motifs present in bacterial DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma. Proc. Natl Acad. Sci. USA 93, 2879-2883 (1996).
122. Wang, R. et al. Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine. Science 282, 476-480 (1998).
123. Hanke, T., Schneider, J., Gilbert, S. C., Hill, A. V. S. & McMichael, A. DNA multi-CTL epitope vaccines for HIV and Plasmodium falciparum: immunogenicity in mice. Vaccine 16, 426-435 (1998).
124. + cytotoxic T lymphocytes: a novel approach to vaccine design. J. Virol. 72, 2246-2252 (1998).
125. Velders, M. P. et al. Defined flanking spacers and enhanced proteolysis is essential for eradication of established tumors by an epitope string DNA vaccine. J. Immunol. 166, 5366-5373 (2001).
126. Moss, B. Vaccinia virus: a tool for research and vaccine development. Science 252, 1662-1667 (1991).
127. Sullivan, N. J., Sanchez, A., Rollin, P. E., Yang, Z. Y. & Nabel, G. J. Development of a preventive vaccine for Ebola virus infection in primates. Nature 408, 605-609 (2000).
128. Hanke, T. et al. Enhancement of MHC class I-restricted peptide-specific T cell induction by a DNA prime/MVA boost vaccination regime. Vaccine 16, 439-445 (1998).
129. Kent, S. J. et al. Enhanced T-cell immunogenicity and protective efficacy of a human immunodeficiency virus type 1 vaccine regimen consisting of consecutive priming with DNA and boosting with recombinant fowlpox virus. J. Virol. 72, 10180-10188 (1998).
130. Amara, R. R. et al. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science 292, 69-74 (2001).
131. Scheerlinck, J. Y. et al. The immune response to a DNA vaccine can be modulated by co-delivery of cytokine genes using a DNA prime-protein boost strategy. Vaccine 19, 4053-4060 (2001).
132. Billaut-Mulot, O., Idziorek, T., Loyens, M., Capron, A. & Bahr, G. M. Modulation of cellular and humoral immune responses to a multiepitopic HIV-1 DNA vaccine by interleukin-18 DNA immunization/viral protein boost. Vaccine 19, 2803-2811 (2001).
133. Boyer, J. D. et al. Vaccination of seronegative volunteers with a human immunodeficiency virus type 1 env/rev DNA vaccine induces antigen-specific proliferation and lymphocyte production of β-chemokines. J. Infect. Dis. 181, 476-483 (2000).
134. Banchereau, J. & Steinman, R. M. Dendritic cells and the control of immunity. Nature 392, 245-252 (1998).
135. Sigal, L. J. & Rock, K. L. Bone marrow-derived antigen-presenting cells are required for the generation of cytotoxic T lymphocyte responses to viruses and use transporter associated with antigen presentation (TAP)-dependent and- independent pathways of antigen presentation. J. Exp. Med. 192, 1143-1150 (2000).
136. Lenz, L. L., Sutz, E. A. & Bevan, M. J. Requirements for bone marrow-derived antigen-presenting cells in priming cytotoxic T cell responses to intracellular pathogens. J. Exp. Med. 192, 1135-1142 (2000).
137. Gabrilovich, D. I. et al. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nature Med. 2, 1096-1103 (1996); erratum 2, 1267 (1996).
138. Shearer, G. M. HIV-induced immunopathogenesis. Immunity 9, 587-593 (1998).
139. + T cells specific for a single nonamer epitope of Listeria monocytogenes are protective in vivo. J. Exp. Med. 175, 1531-1538 (1992).
140. + CTL by immunization with syngeneic irradiated HIV-1 envelope derived peptide-pulsed dendritic cells. Int. Immunol. 5, 849-857 (1993).
141. Gabrilovich, D. I., Nadaf, S., Corak, J., Berzofsky, J. A. & Carbone, D. P. Dendritic cells in anti-tumor immune reponses. II. Dendritic cells grown from bone marrow precursors, but not mature DC from tumor-bearing mice are effective antigen carriers in the therapy of established tumors. Cell. Immunol. 170, 111-119 (1996).
142. Zitvogel, L. et al. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines. J. Exp. Med. 183, 87-97 (1996).
143. Paglia, P., Chiodoni, C., Rodolfo, M. & Colombo, M. P. Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo. J. Exp. Med. 183, 317-322 (1996).
144. Labeur, M. S. et al. Generation of tumor immunity by bone marrow-derived dendritic cells correlates with dendritic cell maturation stage. J. Immunol. 162, 168-175 (1999).
145. Mackey, M. F. et al. Dendritic cells require maturation via CD40 to generate protective antitumor immunity. J. Immunol. 161, 2094-2098 (1998).
146. Diehl, L. et al. CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy. Nature Med. 5, 774-779 (1999).
147. Dhodapkar, M. V. et al. Rapid generation of broad T-cell immunity in humans after a single injection of mature dendritic cells. J. Clin. Invest. 104, 173-180 (1999).
148. + T-cell in humans without foreign helper epitopes. J. Clin. Invest. 105, R9-R14 (2000).
149. Mueller, D. L., Jenkins, M. K. & Schwartz, R. H. Clonal expansion versus functional clonal inactivation: a costimulatory signalling pathway determines the outcome of T cell antigen receptor occupancy. Annu. Rev. Immunol. 7, 445-480 (1989).
150. Roncarolo, M. G., Levings, M. K. & Traversari, C. Differentiation of T regulatory cells by immature dendritic cells. J. Exp. Med. 193, F5-F9 (2001).
151. + CTL in vivo with peptide vaccine constructs. J. Immunol. 152, 549-556 (1994).
152. + T-helper and a T-killer cell. Nature 393, 474-478 (1998).
153. Bennett, S. R. M. et al. Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature 393, 478-480 (1998).
154. Schoenberger, S. P., Toes, R. E. M., van derVoort, E. I. H., Offringa, R. & Melief, C. J. M. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature 393, 480-483 (1998).
155. Pulendran, B., Banchereau, J., Maraskovsky, E. & Maliszewski, C. Modulating the immune response with dendritic cells and their growth factors. Trends Immunol. 22, 41-47 (2001).
156. Banchereau, J. et al. Immunobiology of dendritic cells. Annu. Rev. Immunol. 13, 767-811 (2000).
157. H2 development. Nature Immunol. 1, 199-205 (2000).
158. Albert, M. L., Sauter, B. & Bhardwaj, N. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature 392, 85-89 (1998).
159. Berard, F. et al. Cross-priming of naive CD8 T cells against melanoma antigens using dendritic cells loaded with killed allogeneic melanoma cells. J. Exp. Med. 192, 1535-1544 (2000).
160. + T-cell responses from chronically infected individuals. J. Virol. 75, 2142-2153 (2001).
161. Mitchell, D. A. & Nair, S. K. RNA-transfected dendritic cells in cancer immunotherapy. J. Clin. Invest. 106, 1065-1069 (2000).
162. Boczkowski, D., Nair, S. K., Nam, J. H., Lyerty, H. K. & Gilboa, E. Induction of tumor immunity and cytotoxic T lymphocyte responses using dendritic cells transfected with messenger RNA amplified from tumor cells. Cancer Res. 60, 1028-1034 (2000).
163. Sallusto, F. & Lanzavecchia, A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor α. J. Exp. Med. 179, 1109-1118 (1994).
164. Thurner, B. et al. Generation of large numbers of fully mature and stable dendritic cells from leukapheresis products for clinical application. J. Immunol. Methods 223, 1-15 (1999).
165. Mosca, P. J. et al. A subset of human monocyte-derived dendritic cells expresses high levels of interleukin-12 in response to combined CD40 ligand and interferon-γ treatment. Blood 96, 3499-3504 (2000).
166. Fong, L. & Engleman, E. G. Dendritic cells in cancer immunotherapy. Annu. Rev. Immunol. 18, 245-273 (2000).
167. Wong, E. C. C. et al. Development of a clinical-scale method for generation of dendritic cells from PBMC for use in cancer immunotherapy. Cytotherapy 3, 19-29 (2001).
168. Mulé, J. J. Dendritic cells: at the clinical crossroads. J. Clin. Invest. 105, 707-708 (2000).
169. Dallal, R. M. & Lotze, M. T. The dendritic cell and human cancer vaccines. Curr. Opin. Immunol. 12, 583-588 (2000).
170. Thurner, B. et al. Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J. Exp. Med. 190, 1669-1678 (1999).
171. Nestle, F. O. et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nature Med. 4, 328-332 (1998).
172. Weber, J. S. & Aparicio, A. Novel immunologic approaches to the management of malignant melanoma. Curr. Opin. Oncol. 13, 124-128 (2001).
173. Hsu, F. J. et al. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nature Med. 2, 52-58 (1995).
174. Liso, A. et al. Idiotype vaccination using dendritic cells after autologous peripheral blood progenitor cell transplantation for multiple myeloma. Biol. Blood Marrow Transplant. 6, 621-627 (2000).
175. Pulendran, B. et al. Flt3-ligand and granulocyte colony-stimulating factor mobilize distinct human dendritic cell subsets in vivo. J. Immunol. 165, 566-572 (2000).
176. Boyer, J. D. et al. HIV-1 DNA vaccines and chemokines. Vaccine 17 (Suppl. 2), S53-S64 (1999).
177. + CTL tumor immunosurveillance and regulation of tumor escape by CD4 T cells through an effect on quality of CTL. J. Immunol. 163, 184-193 (1999).
178. Ohodapkar, M. V., Steinman, R. M., Krasovsky, J., Munz, C. & Bhardwaj, N. Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells. J. Exp. Med. 193, 233-238 (2001).